School of Population Health, University of Adelaide, South Australia, Australia; Vaccinology and Immunology Research Trials Unit (VIRTU), University of Adelaide, Women's and Children's Hospital, South Australia, Australia.
School of Population Health, University of Adelaide, South Australia, Australia.
Vaccine. 2014 Jul 16;32(33):4214-9. doi: 10.1016/j.vaccine.2014.04.046. Epub 2014 Jun 9.
To determine factors influencing Family Physician (FP) uptake of non government-funded vaccines, and to explore FP attitudes towards the introduction and use of a new vaccine to protect against serogroup B meningococcal disease to inform its future introduction into the Australian Immunisation Schedule.
Quantitative, self-administered state-wide questionnaire mailed to all FPs in South Australia (n=1786). Results from 523 FP respondents in South Australia, collected between June and October 2013.
Self-reported immunisation counselling practices; and knowledge, attitudes and barriers to prescribing of Meningococcal B (Men B) vaccine and other recommended, non-funded immunisations.
The response rate was 30% (n=523). While most (59%) respondents had worked in general practice for over 20 years, only 39% of all respondents had ever had personal or professional experience with a case of invasive meningococcal disease (IMD). Most FPs (63%) were aware that a meningococcal B vaccine was being developed, and 93% of respondents agreed that this vaccine should be government-funded. FPs ranked Men B vaccine as the highest priority to receive funding of eight currently non-funded immunisation strategies. High vaccine cost and low patient socioeconomic status were identified as definite barriers to prescribing non-funded vaccines by 59% of respondents. Past IMD experience significantly affected attitudes and prescribing practices.
IMD, while encountered rarely in clinical practice, is considered an important disease to vaccinate against by FPs. Cost and perceived low socioeconomic status of patients are substantial barriers to FPs prescribing Men B and other non-funded vaccines, and inclusion of such vaccines on the National Immunisation Program is likely to improve equity of access.
确定影响家庭医生（FP）接种非政府资助疫苗的因素，并探讨 FP 对引进和使用预防 B 群脑膜炎球菌疾病的新疫苗的态度，以为其未来纳入澳大利亚免疫计划提供信息。
设计、地点和参与者：对南澳大利亚州所有 FP 进行了定量、自我管理的全州范围的邮寄问卷调查（n=1786）。于 2013 年 6 月至 10 月期间收集了南澳大利亚州 523 名 FP 答复者的结果。
自我报告的免疫咨询实践；以及对脑膜炎球菌 B（Men B）疫苗和其他推荐的非资助免疫接种的知识、态度和障碍的认识。
回应率为 30%（n=523）。尽管大多数（59%）答复者在普通科医生工作超过 20 年，但只有 39%的所有答复者有过侵袭性脑膜炎球菌病（IMD）的个人或专业经验。大多数 FP（63%）知道正在开发脑膜炎球菌 B 疫苗，93%的答复者同意该疫苗应由政府资助。FP 将 Men B 疫苗列为八种目前非资助免疫接种策略中获得资金的最高优先事项。59%的答复者认为疫苗费用高和患者社会经济地位低是开具非资助疫苗的明确障碍。过去的 IMD 经验显著影响了态度和处方实践。
尽管在临床实践中很少遇到 IMD，但 FP 认为这是一种重要的疫苗接种疾病。成本和患者感知的社会经济地位低是 FP 开具 Men B 和其他非资助疫苗的重要障碍，将此类疫苗纳入国家免疫计划可能会提高获得机会的公平性。
